Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Neuroscience
Volume 15, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-04
DOI
10.3389/fnins.2021.733857
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aducanumab and the FDA — where are we now?
- (2021) Howard Fillit et al. Nature Reviews Neurology
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- (2021) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
- (2020) Dieter Volc et al. LANCET NEUROLOGY
- Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
- (2020) Steven S. Plotkin et al. NEUROBIOLOGY OF DISEASE
- Invite Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials
- (2020) D. Boche et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
- (2020) Wassilios G. Meissner et al. MOVEMENT DISORDERS
- Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
- (2020) Jacqui T. Nimmo et al. Alzheimers Research & Therapy
- Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?
- (2019) Francesco Panza et al. ANNALS OF NEUROLOGY
- A walk through tau therapeutic strategies
- (2019) Santosh Jadhav et al. Acta Neuropathologica Communications
- Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
- (2019) Claire Leurent et al. Annals of Clinical and Translational Neurology
- Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review
- (2019) Marie-Aleth Lacaille-Dubois PHYTOMEDICINE
- Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
- (2019) James A R Nicoll et al. BRAIN
- Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
- (2019) Darren J. Schofield et al. NEUROBIOLOGY OF DISEASE
- ABBY
- (2018) Jeffrey L. Cummings et al. NEUROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
- (2018) Stina Syvänen et al. Alzheimers Research & Therapy
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- (2018) Joseph Jankovic et al. JAMA Neurology
- 39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period
- (2018) Gary B. Freeman et al. JOURNAL OF ALZHEIMERS DISEASE
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
- (2018) Kristina Magnusson et al. JOURNAL OF ALZHEIMERS DISEASE
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
- (2018) Stephen Salloway et al. Alzheimers Research & Therapy
- SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
- (2018) Laurent Pradier et al. Alzheimers Research & Therapy
- Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
- (2018) Andreas Weihofen et al. NEUROBIOLOGY OF DISEASE
- Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies
- (2017) Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
- (2016) Michael C. Irizarry et al. Alzheimers & Dementia
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
- (2016) Eric R. Siemers et al. Alzheimers & Dementia
- Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
- (2016) Jing Liu et al. DRUGS & AGING
- Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
- (2016) Francesco Panza et al. Immunotherapy
- Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease
- (2016) Florence Pasquier et al. JOURNAL OF ALZHEIMERS DISEASE
- A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies
- (2016) Dante J. Marciani JOURNAL OF NEUROCHEMISTRY
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
- (2016) Adrian Ivanoiu et al. Alzheimers Research & Therapy
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- (2016) Rik Vandenberghe et al. Alzheimers Research & Therapy
- In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy
- (2016) Mathieu D. Santin et al. Frontiers in Aging Neuroscience
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
- (2016) Mark Ultsch et al. Scientific Reports
- Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
- (2015) Yvonne Bouter et al. ACTA NEUROPATHOLOGICA
- Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
- (2015) James P. Fuller et al. ACTA NEUROPATHOLOGICA
- Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity
- (2015) Kelly R. Bales et al. BRAIN
- Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
- (2015) Heii Arai et al. Current Alzheimer Research
- Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice
- (2015) Alexandra J. Mably et al. NEUROBIOLOGY OF DISEASE
- Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β
- (2015) Jay Amin et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
- (2015) Elvira Valera et al. Neurotherapeutics
- Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines
- (2015) Markus Mandler et al. PLoS One
- Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
- (2015) Martin R Farlow et al. Alzheimers Research & Therapy
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
- (2014) D. Games et al. JOURNAL OF NEUROSCIENCE
- Combined Treatment with a BACE Inhibitor and Anti-A Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice
- (2014) H. Jacobsen et al. JOURNAL OF NEUROSCIENCE
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Active immunotherapy options for Alzheimer’s disease
- (2014) Bengt Winblad et al. Alzheimers Research & Therapy
- Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
- (2013) Wagner Zago et al. Alzheimers & Dementia
- Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
- (2013) Elina Zotova et al. BRAIN
- Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
- (2013) Aaron H. Burstein et al. CLINICAL NEUROPHARMACOLOGY
- Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease
- (2013) Jaren W. Landen et al. CLINICAL NEUROPHARMACOLOGY
- Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
- (2013) Izuru Miyoshi et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Mechanisms of Action of Adjuvants
- (2013) Sunita Awate et al. Frontiers in Immunology
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
- (2012) Gary B. Freeman et al. Current Alzheimer Research
- Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
- (2012) Frédérique Bard et al. EXPERIMENTAL NEUROLOGY
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
- (2012) Reisa Sperling et al. LANCET NEUROLOGY
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- The Aβ peptide conjugate vaccine, acc-001, generates n-terminal anti- Aβ antibodies in the absence of Aβ directed t-cell responses
- (2011) Michael Hagen et al. Alzheimers & Dementia
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease
- (2011) Kazunori Uenaka et al. CLINICAL NEUROPHARMACOLOGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- AFFITOME® technology in neurodegenerative diseases: The doubling advantage
- (2011) Achim Schneeberger et al. Human vaccines & immunotherapeutics
- Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
- (2011) Sherry L. La Porte et al. JOURNAL OF MOLECULAR BIOLOGY
- The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
- (2011) C. Wiessner et al. JOURNAL OF NEUROSCIENCE
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- Microglial alterations in human Alzheimer's disease following Aβ42 immunization
- (2010) E. Zotova et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection
- (2009) Karen Smith Korsholm et al. IMMUNOLOGY
- Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing
- (2009) A. Schneeberger et al. Journal of Nutrition Health & Aging
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores
- (2008) Sid E. O’Bryant ARCHIVES OF NEUROLOGY
- Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
- (2008) D. Boche et al. BRAIN
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Peripheral A subspecies as risk biomarkers of Alzheimer's disease
- (2008) N. Schupf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started